Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
February 15, 2007

BioFocus to Provide Lead-Optimization for Compound that Induces Tumor-Cell Suicide

  • Galapagos and the University of Bristol entered into a new discovery collaboration in the field of cancer research. Galapagos' service division, BioFocus, will provide lead-optimization services for the University’s research program focusing on destroying cancer cells.

    Total contract value for Galapagos exceeds Euro $2M in research fees over two years.

    Scientists at ProXara Biotechnology, a spin-out from the University of Bristol, discovered drug-like compounds that prevent PKB activation and make tumor cells commit suicide. BioFocus will apply its Admensa technology to help optimize these drug-like compounds and select a candidate for clinical trials.

  • You’re all set! Thank you for subscribing to GEN Highlights.